The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.

If you're struggling with chronic low back pain, then this is for you. Brad: So we're going to show you three different ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

In conclusion, the study demonstrates the potential of brain biomarkers like CME and PAF to revolutionize pain management. By ...

A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment.

Chronic pain affects approximately 1 in 5 Americans, and yet it remains one of the most misunderstood and challenging medical ...

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...

HB 241 would require health insurers to cover physical therapy, acupuncture, massage therapy, and chiropractic care as ...

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...